Five hexapeptide and heptapeptide analogs of luteiniSng hormone-releasing hormone (LH-RH) were synthesized for use as carriers for cytotoxic compounds. These short analogs were expected to enhanc target selectivity of the antineoplastic agents linked to them. Native LH-RH-(3-9) and LH-RH-(4-9) containing D-lysine and D-ornithine at position 6 were anidated with ethylamine and acylated on the N termi- More than 2500 agonistic and antagonistic analogs of luteinizing hormone-releasing hormone (LH-RH) have been synthesized since the discovery and structural elucidation (1) of LH-RH in view of their expected medical application (2-4). In addition to the various endocrine and gynecological applications of some of these analogs, they may be potential therapeutic agents in the treatment of hormone-sensitive tumors, like prostate cancer and breast cancer.
nus. The receptor-binding afnity of one hexapeptide carrier AJ-41 (Ac-Ser-Tyr-D-Lys-Leu-Arg-Pro-NH-Et) to human breast cancer cell membranes was similar to that of [D-Trp'JLH-RH. Alkylating nitrogen mutrs (melphalan, Ac-melphalan), anthraquinone derivatives including anticancer antibiotic doxorubicin, antimetabolite (methotrexate), and cisplatin-like platinum complex were linked to these peptides through their Br-amino group at position 6. The hybrid molecules showed no LH-RH agonistic activity in to and in vivo but had nontypical antagonistic effects on pituitary cells in vio at the doses tested. These analogs showed a wide range of receptor-binding affinities to rat pituitaries and cell membranes of human breast cancer and rat Dunning prostate cancer. Several of these coqjugates exerted some cytotoxic effects on MCF-7 breast cancer cell line.
More than 2500 agonistic and antagonistic analogs of luteinizing hormone-releasing hormone (LH-RH) have been synthesized since the discovery and structural elucidation (1) of LH-RH in view of their expected medical application (2) (3) (4) . In addition to the various endocrine and gynecological applications of some of these analogs, they may be potential therapeutic agents in the treatment of hormone-sensitive tumors, like prostate cancer and breast cancer.
The synthetic effort was directed toward finding potent agonists and antagonists by changing amino acids at certain positions, using D-form and/or unusual amino acids. However, only a few reports deal with analogs with shortened LH-RH peptide chain. Deletion of N-or C-terminal amino acids causes a dramatic loss of activity. In 1973-1974 Rivier et al. (5, 6 ) synthesized a series of short-chain LH-RH analogs to find the smallest fragments biologically active by shortening the decapeptide sequence first at the N terminal and, in another series, shortening it at the C terminal. They found that these peptides had only marginal activity, except for [des-Gly10]LH-RH, which had 10%6 activity of the parent hormone. Although the free acid analogue of LH-RH exhibited very low potency, replacement of the C-terminal Gly-NH2 with alkylamides resulted in peptides significantly more active than LH-RH itself (7, 8) . Sandow and Konig (9) examined fragments of LH-RH agonist buserelin ([DSer(OBu9)6,Pro9-NHEtJLH-RH where OBu' is t-butoxy), and they found buserelin-(3-9) to be the smallest fragment possessing significant ovulatory activity. Recently, Haviv et al. (10) synthesized and tested several reduced-size hexapeptide analogs. Their results showed a wide range of binding affinities (equal to or even exceeding that of LH-RH) to pituitary cell membrane. Depending on the nature of the substituent in positions 4 and 6, the biological responses could be agonistic or antagonistic. Some of their peptides exerted significant antagonistic effect. They suggested that these LH-RH-(4-9) analogs may become useful agents in the treatment of various endocrine disorders.
LH-RH agonists and antagonists with high binding affinity to human breast cancer cell membrane can serve as carriers for cytotoxic compounds (11) (12) (13) and target the chemotherapeutic agents to the receptors of cancerous tissues. In the present paper we report the synthesis ofreduced-size LH-RH analogs carrying various cytotoxic alkylating agents, anthraquinone derivatives, antimetabolite methotrexate (MTX), and Cisplatin (cis-diamminedichloroplatinum)-like platinum complex (Fig. 1 ).
MATERIALS AND METHODS
Precursor Peptides. Reduced-size LH-RH analogs were synthesized on chloromethyl resin (1 milliequivalent of Cl per g, Bachem) by standard solid-phase peptide synthesis (14) starting with anchoring tert-butoxycarbonyl (Boc)-Pro by the KF method (15) . Peptides were built step-by-step, coupling Boc-Arg(tosylguanidino), Boc-Leu-, Boc-D-Lys(2-Cl-Z)-, Boc-D-ornithine(Z)-, Boc-Tyr(C12BzI)-, and Boc-Ser(Bzl)-protected amino acids, where Bzl is benzyl and Z is benzyloxycarbonyl (Bachem), using in situ preformed 1-hydroxybenzotriazole esters. The N terminus of serine was acylated with Ac-Trp, indole-3-acetic acid (IA), or with 10-fold excess ofacetic anhydride. Peptides were cleaved from the resins by treatment with anhydrous ethylamine in dimethylformamide, 1:1 (vol/vol) for 2 days at room temperature. Protective groups were removed by HF (10 ml/g ofpeptide-resin) at 00C for 30 min and then at room temperature for an additional 30 min. After elimination of HF, the residue was washed with diethyl ether, and-the peptide was dissolved in 50%o (vol/vol) aqueous AcOH. The crude product thus obtained was purified by preparative HPLC [Dynamax Macro column (21.2 x 250 mm) packed with spherical C18 silica gel (300-A pore size, 12-gm particle size) (Rainin, Woburn, MA) using a linear gradient of solvent system i consisting of 0. Peptides containing cytotoxic groups were purified on a W-Porex C18 column (10 x 250 mm; pore size, 300 A; particle size, 5 ,um) (Phenomenex, Rancho Palos Verdes, CA) using solvent system i or solvent system ii consisting of 0.2% aqueous acetic acid (A) and 0.2%o acetic acid in 70% aqueous acetonitrile (B) in a gradient mode. Column eluant was monitored with UV detectors operating at 230 or 280 nm. Chromatography was done at ambient temperature.
LH-releasing and LH-RH-inhibiting activities. The ability of compounds to influence LH release in vitro was assayed by using a dispersed rat pituitary cell superfusion system (16) .
LH-releasing effect was determined by perfusing the analogs through the cells for 3 min in a 1-ml vol of perfusate at 0.1-to 10-nM concentrations. LH content of 1-ml fractions collected was determined by RIA. The potency of peptides was compared to that of 3 nM LH-RH perfused in the same way.
LH-RH inhibiting effect of analogs was tested as follows: each peptide was perfused through the cells for 9 min in a 3-ml vol at 10 or 30 nM concentrations. Next, a mixture containing the same concentration of analog and 3 nM LH-RH was immediately administered for 3 min. This step was followed by four consecutive infusions of 3 nM LH-RH for 3 min (1 ml of perfusate) at 30-min intervals (30, 60, and 90 min). LH content of the 1-ml fractions collected was determined by RIA.
In vivo test. Male rats weighing 380-450 g were castrated 3 weeks before the experiment, anesthetized with Metofane, and injected s. (3) To facilitate the incorporation of some chemotherapeutic agents into position R4, peptide XII was derivatized at that position either by acylation of its D-lysine residue with glutaric anhydride (peptide XIV) or with 2,3-diaminopropionic acid (peptide XIII). After purification by preparative HPLC, the purity of the isolated peptides was >96%. Hydrophobicity ofthe series was assessed by the capacity factor (K') obtained on analytical HPLC (Table 1) . K' values of carriers containing indole ring at the N terminal (peptides I, III, VI, and IX) were seven times higher than that of peptide XII. IA or Ac-Trp substitution changed the hydrophobicity Endocrine Effects of These Analogs. Table 3 shows that the analogs did not function as true antagonistic compounds. The increase in the inhibitory effect on the LH response with time with peptides VI, XII, and XIII is probably from secondary processes. The analogs showed no agonistic activity in vitro Table 3 . LH-RH antagonistic activity of R'-Ser-Tyr-R4(Q)-LeuArg-Pro-NHEt peptides (see Table 1 II  10  15  32  41  44  III  10  0  11  12  0  41  45  IV  10  12  33  30  41  36  50  V  30  14  21  32  33  47  VI  10  0  18  31  38  VII  10  3  4  14  21  VIII  30  18  3  14  IX  10  3  7  15  0  36  45  X  10  13  33  33  36  XI  30  19  22  33  26  55  XII  10  0  12  20  27  33  57  XIII  10  6  20  21  31  24  29  XV  10  1  11  22  32  XVI  30  0  0  0  0  33  22  XVII  38  48   XVIII  30  0  0  0  -33  57  XIX  30  0  3  29  -40  53  XX  30  14  19  37  -XXI  30  2  8  13  19  40 at the doses tested (0.1-10 nM). One of the short-chain LH-RH analogs, AJ-41, was selected for in vivo tests in castrated rats and compared with a well-known LH-RH antagonist SB-75. Analog AJ-41 showed no LH-suppressing activity at a dose of 500 Itg per rat, whereas analog SB-75 produced a 100%o LH inhibition at a dose of 5 pAg per rat (Fig.   2 ). As expected, analog AJ41 did not induce LH release at this dose, which is 1000 times higher than the active dose of LH-RH. Fig. 1 shows the cytotoxic compounds that were coupled to carrier peptides. e-Amino side-chain group at position 4 was acylated directly with melphalan, acetyl melphalan, and MTX, whereas HMAQ and DOX were connected through a bridge molecule (glutaric acid). Platinum complex (peptide XX) was formed by chelating platinum with the two amino groups of the A2pr side chain of peptide XIII. The same starting compound was used to incorporate two molecules of HMAQ (peptide XXI). Peptide XII was the most hydrophilic peptide among our carrier compounds, and its derivatives preserved this character (Table 1) -that is, the capacity factors of cytotoxic conjugates with the backbone of peptide XII were lower than those of the other peptide bearing the same substituents (peptide II > peptides XV and peptide V > peptide XVIII). Nonspecific activation of the two carboxyl groups of the glutaric acid moiety in MTX resulted in two isomeric conjugates (peptide XVI) with carrier XII. Although the high resolution of our HPLC system enabled us to detect the two isomers, their separation was not done.
A similar nontypical inhibition of LH response was found when peptides with cytotoxic moieties were tested for antagonistic activity (Table 3) . Nearly all the compounds showed increased inhibitory effect with time; however, none of them exerted significant antagonistic activity at 0 min when infused at relatively high 10 to 30 nM concentrations.
The effect of analogs on [3H]thymidine incorporation was evaluated in cell cultures of MCF-7 human breast cancer cell line (Table 3 ). All analogs tested reduced [3H]thymidine incorporation, especially peptide XII; peptides XVIII and XIX also had high cytotoxic activity.
DISCUSSION
Although a large number of LH-RH analogs were made, only a few shortened peptides were synthesized and investigated for their biological potencies (5, 6, 9) . With few exceptions (7, 8) , these shortened analogs had low LH-RH agonistic activity. To evaluate in vitro potencies and to study the structureactivity relationships, 29 hexapeptide and heptapeptide analogs with agonistic or antagonistic activity were synthesized by Haviv et al. (10) and antagonistic activity is influenced by substituents in these positions. Their results suggest that there is an optimal size, length, and shape for substituents at position 1 for achieving affinity, potency, and agonistic versus antagonistic activity (10) . Our peptide carriers had no LH-releasing activity or true LH-RH inhibiting activity at the doses tested. Binding affinity of these hexapeptide analogs, produced by replacing IA1 with Ac-Trpl (peptides I-IX), depended on the substituent in position 4 and on the type oftissue membrane examined. The relatively high binding affinity of compound XII to breast cancer cell membranes and good binding to pituitary cell membranes is noteworthy, considering that compound XII contains only six amino acids and no bulky substituent in position 1. The Gly6 replacement in LH-RH antagonists by D-amino acid residues led to peptides with enhanced antagonistic potency (2, 3, 19) .
We incorporated D-lysine or D-ornithine into position 4 (position 6 in LH-RH), which resulted in peptides with a free amino group in the side chain. Changing D-lysine to D-ornithine in analogs with IA at position 1 (peptides I and III) increased the receptor-binding affinity to human breast cancer receptors, whereas in the case of analogs with Ac-Trp at position 1 (peptides VI and IX), we found no binding (Tables   1 and 2 ). We could demonstrate differences between the nontypical LH-RH inhibition by peptides containing D-Lys4 (peptides VI, XII, and XIII) and D-Orn4 (peptides III and IX) ( (13) .
From our recent studies on LH-RH analogs with cytotoxic moieties (11-13, 24 ), we selected those cytotoxic compounds that proved useful for coupling to the side chain of LH-RH agonists and antagonists (Fig. 1) Hexapeptide carrier AJ-41 had no endocrine effects in vivo on LH release in doses 1000 times greater than LH-RH (Fig. 2) . To elucidate these complex effects and to discover the mechanism of action of these short-chain cytotoxic LH-RH analogs and their carriers will require extensive additional studies both in vivo and in vitro.
